source
- Apnimed targets up to $160 million IPO to fund launch of Oxnimbi, its oral sleep apnea pillApnimed, a Massachusetts biotech, filed with the SEC indicating it will seek an IPO of up to $160 million to finance the commercial launch of its oral obstructive sleep apnea therapy, Oxnimbi (AD10…
- MapLight shares tumble over 60% after mixed Phase 2 schizophrenia trial resultsMapLight Therapeutics reported mixed outcomes from its Phase 2 Zephyr trial of the experimental schizophrenia drug ML-007C-MA, causing its stock to fall sharply. The trial enrolled 307 patients wi…